Selexipag and Abrocitinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Selexipag
Abrocitinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Selexipag (Uptravi) is used for pulmonary arterial hypertension, and it has effects on platelets that can make it a little harder for your blood to clot. Abrocitinib (Cibinqo) is used for eczema, and it can also affect your platelets and raise bleeding risk, especially in the first few months you take it.
Put together, these two can add up and increase your chance of bleeding, like easy bruising, nosebleeds, or bleeding that is slow to stop. Because of this, the combination is not recommended, especially early in abrocitinib treatment. Please don't stop either medicine on your own. Talk with your pharmacist or doctor so they can choose the safest plan for you.
Interaction: Additive antiplatelet/antihemostatic effects increasing bleeding risk.
- Mechanism: Pharmacodynamic (additive), not a metabolic interaction. Selexipag is a prostacyclin (IP) receptor agonist with inherent antiplatelet activity; abrocitinib can impair platelet function, particularly during the first 3 months of therapy.
- Direction/effect: Increased bleeding risk from additive effects on hemostasis.
- Severity: Contraindicated per labeling (antiplatelet agents other than low-dose aspirin ≤81 mg/day) during the initial 3 months of abrocitinib.
- Evidence: Theoretical.
- Management: Avoid concurrent use in this window; if therapy is unavoidable, individualize and monitor closely for bleeding. Coordinate care between prescribers.
What happens
Increased risk of bleeding
Interaction Deep Dive
During the initial 3 months of therapy, giving abrocitinib together with antiplatelet drugs is contraindicated because of a heightened bleeding risk, with the exception of low-dose aspirin (up to 81 mg per day)1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
Your care team takes this seriously because both drugs can raise bleeding risk, and the combination is generally avoided during the first few months of abrocitinib therapy.
- Keep taking both exactly as prescribed until you speak with your prescriber. Do not stop either one on your own.
- Your team may choose an alternative, adjust timing, or monitor you more closely for bleeding, and the plan will be individualized for you.
- Watch for and report unusual bruising, nosebleeds, blood in urine or stool, black stools, or bleeding that won't stop.
- Tell your pharmacist and doctor that you take both so they can coordinate the safest option.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Selexipag and Abrocitinib together?
Combining selexipag with abrocitinib can add up to a higher bleeding risk and is generally avoided, especially in the first 3 months of abrocitinib. Do not stop either drug on your own; contact your prescriber or pharmacist to pick the safest plan. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Selexipag and Abrocitinib interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Selexipag and Abrocitinib interaction managed?
Your care team takes this seriously because both drugs can raise bleeding risk, and the combination is generally avoided during the first few months of abrocitinib therapy. Keep taking both exactly as prescribed until you speak with your prescriber. Do not stop either one on your own. Your team may choose an alternative, adjust timing, or monitor you more closely for bleeding, and the plan will be… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Selexipag or Abrocitinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CIBINQO(TM) oral tablets, abrocitinib oral tablets. Pfizer Labs (per FDA), New York, NY, 2022. DailyMed
Keep reading about Selexipag
Keep reading about Abrocitinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist